The following is a summary of "Clinicopathologic and genomic analyses of SMARCA4-mutated non-small cell lung carcinoma ...
MyChesCo on MSN11d
Prelude Therapeutics Reports 2024 Financial Results and Clinical Pipeline AdvancementsPrelude Therapeutics Incorporated (Nasdaq: PRLD) has released its 2024 financial results and provided an update on its ...
WILMINGTON, DE — Prelude Therapeutics Incorporated this week unveiled interim results from its Phase 1 trial of PRT3789, a ...
Reports FY24 revenue $7M vs. $0 last year. “2024 was a productive year for Prelude highlighted by our efforts to advance the first ever highly ...
“2024 was a productive year for Prelude highlighted by our efforts to advance the first ever highly selective SMARCA2 degraders to treat cancer patients who harbor SMARCA4 deleterious mutations ...
14d
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity ...
PRT3789 has demonstrated clinical proof-of-concept that selectively degrading SMARCA2 is generally safe and has monotherapy anti-tumor activity in patients with SMARCA4-deficient, non-small cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback